Laboratory:Akiruno

Laboratory:Akiruno
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
Aldosterone〔CLEIA〕
|
Plasma
0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
4.0-82.1(pg/mL) |
Aldosterone〔CLEIA〕
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
4.0-82.1(pg/mL) |
Aldosterone〔CLEIA〕
|
Urine storage
1.5 |
A00 |
![]() (21 days) |
5-7 |
CLEIA |
1.0-19.3 (μg/day) | |
Active renin concentration(ARC)〔CLEIA〕
|
Plasma
0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
2.21-39.5(pg/mL) |
Plasma renin activity (PRA)〔EIA〕
|
![]() Plasma 0.7 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 |
Enzyme immunoassay(EIA) |
Lying position 0.2-2.3 Sitting position 0.2-3.9 Standing position 0.2-4.1 (ng/mL/hr) |
Aldosterone 〔CLEIA〕/renin concentration ratio
|
Plasma
1.0 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
See below |
Aldosterone 〔CLEIA〕/renin activity ratio
|
![]() Plasma 1.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 | Aldosterone: CLEIA Renin activity: EIA | See below |
Cyclic AMP
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() (1 month) |
Please contact us in advance. |
RIA DCC method |
11-21(pmol/mL) |
Cyclic AMP
|
Urine storage
1 |
U00 |
![]() |
Please contact us in advance. |
RIA DCC method |
1.8-6.3(μmol/day) | |
Human atrial natriuretic peptide (HANP)
|
![]() Plasma 0.5 |
PAP ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
43.0 or less (pg/mL) |
Human brain natriuretic peptide (BNP)
|
![]() Plasma 0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA |
18.4 or less (pg/mL) |
N-terminal fragment of human brain natriuretic peptide precursor (NTproBNP)
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA |
125 or less (pg/mL) |
Erythropoietin
|
Serum
0.8 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
CLEIA |
4.2-23.7(mIU/mL) |
Osteocalcin
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA |
Premenopausal women 7.8-30.8 Postmenopausal women 14.2-54.8 Men 8.4-33.1 (ng/mL) |
Undercarboxylated osteocalcin (ucOC)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
ECLIA |
Less than 4.50 (ng/mL) |
Hepatocyte growth factor (HGF)
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-8 |
ELISA |
0.39 or less (ng/mL) |
FGF23〔CLEIA〕
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
4-10 |
CLEIA |
19.9-52.9 (pg/mL) |
Adiponectin〔LA〕
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Latex immunoturbidimetry | 4.0 or more (μg/mL) |
Leptin〔ELISA〕
|
![]() Serum 0.3 |
S09 ↓ A00 |
![]() |
![]() (7 days) |
Please contact us in advance. |
ELISA |
M 0.6-8.9 F 1.9-26.6 (ng/mL) |
sFlt-1/PlGF ratio
|
Serum
0.7 |
S09 ↓ A00 |
![]() |
![]() (7 days) |
2-6 |
ECLIA |
38.0 or less |
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (14 days) |
2-8 |
ELISA |
16-69(pg/mL) |
|
Serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
RIA solid phase method (IRMA) |
2.5-13(ng/mL) | |
|
![]() Plasma 1.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 | Aldosterone: CLEIA Renin activity: EIA | See below |
|
Plasma
1.0 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
See below |
|
![]() Plasma 0.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
6-12 |
RIA2 antibody method |
110 or less (pg/mL) |
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
6-12 |
RIA2 antibody method |
22 or less (pg/mL) |
|
![]() Plasma 0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (20 days) |
2-5 |
RIA solid phase method (IRMA) |
Any time 3.2-36 lying position 2.5-21 standing position 3.6-64 (pg/mL) |
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() (1 month) |
3-5 |
RIA2 antibody method |
Lying position 0.3-2.9 Standing position 0.3-5.4 (ng/mL/hr) |
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
---|---|---|---|---|---|---|---|
Aldosterone〔CLEIA〕
|
Plasma
0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
4.0-82.1(pg/mL) |
Aldosterone〔CLEIA〕
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
4.0-82.1(pg/mL) |
Aldosterone〔CLEIA〕
|
Urine storage
1.5 |
A00 |
![]() (21 days) |
5-7 |
CLEIA |
1.0-19.3 (μg/day) | |
Active renin concentration(ARC)〔CLEIA〕
|
Plasma
0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
2.21-39.5(pg/mL) |
Plasma renin activity (PRA)〔EIA〕
|
![]() Plasma 0.7 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 |
Enzyme immunoassay(EIA) |
Lying position 0.2-2.3 Sitting position 0.2-3.9 Standing position 0.2-4.1 (ng/mL/hr) |
Aldosterone 〔CLEIA〕/renin concentration ratio
|
Plasma
1.0 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
See below |
Aldosterone 〔CLEIA〕/renin activity ratio
|
![]() Plasma 1.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 | Aldosterone: CLEIA Renin activity: EIA | See below |
Cyclic AMP
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() (1 month) |
Please contact us in advance. |
RIA DCC method |
11-21(pmol/mL) |
Cyclic AMP
|
Urine storage
1 |
U00 |
![]() |
Please contact us in advance. |
RIA DCC method |
1.8-6.3(μmol/day) | |
Human atrial natriuretic peptide (HANP)
|
![]() Plasma 0.5 |
PAP ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
43.0 or less (pg/mL) |
Human brain natriuretic peptide (BNP)
|
![]() Plasma 0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
2-4 |
CLEIA |
18.4 or less (pg/mL) |
N-terminal fragment of human brain natriuretic peptide precursor (NTproBNP)
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA |
125 or less (pg/mL) |
Erythropoietin
|
Serum
0.8 |
S09 ↓ A00 |
![]() |
![]() (28 days) |
2-4 |
CLEIA |
4.2-23.7(mIU/mL) |
Osteocalcin
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() |
2-4 |
ECLIA |
Premenopausal women 7.8-30.8 Postmenopausal women 14.2-54.8 Men 8.4-33.1 (ng/mL) |
Undercarboxylated osteocalcin (ucOC)
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
ECLIA |
Less than 4.50 (ng/mL) |
Hepatocyte growth factor (HGF)
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (1 month) |
2-8 |
ELISA |
0.39 or less (ng/mL) |
FGF23〔CLEIA〕
|
Serum
0.4 |
S09 ↓ A00 |
![]() |
![]() (21 days) |
4-10 |
CLEIA |
19.9-52.9 (pg/mL) |
Adiponectin〔LA〕
|
Serum
0.5 |
S09 ↓ A00 |
![]() |
![]() |
2-4 | Latex immunoturbidimetry | 4.0 or more (μg/mL) |
Leptin〔ELISA〕
|
![]() Serum 0.3 |
S09 ↓ A00 |
![]() |
![]() (7 days) |
Please contact us in advance. |
ELISA |
M 0.6-8.9 F 1.9-26.6 (ng/mL) |
sFlt-1/PlGF ratio
|
Serum
0.7 |
S09 ↓ A00 |
![]() |
![]() (7 days) |
2-6 |
ECLIA |
38.0 or less |
|
Serum
0.3 |
S09 ↓ A00 |
![]() |
![]() (14 days) |
2-8 |
ELISA |
16-69(pg/mL) |
|
Serum
0.2 |
S09 ↓ A00 |
![]() |
![]() |
RIA solid phase method (IRMA) |
2.5-13(ng/mL) | |
|
![]() Plasma 1.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() (14 days) |
3-5 | Aldosterone: CLEIA Renin activity: EIA | See below |
|
Plasma
1.0 |
PN2,PN5 ↓ A00 |
![]() |
![]() (21 days) |
2-4 |
CLEIA |
See below |
|
![]() Plasma 0.2 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
6-12 |
RIA2 antibody method |
110 or less (pg/mL) |
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() |
6-12 |
RIA2 antibody method |
22 or less (pg/mL) |
|
![]() Plasma 0.5 |
PN2,PN5 ↓ A00 |
![]() |
![]() (20 days) |
2-5 |
RIA solid phase method (IRMA) |
Any time 3.2-36 lying position 2.5-21 standing position 3.6-64 (pg/mL) |
|
![]() Plasma 0.3 |
PN2,PN5 ↓ A00 |
![]() |
![]() (1 month) |
3-5 |
RIA2 antibody method |
Lying position 0.3-2.9 Standing position 0.3-5.4 (ng/mL/hr) |